SCHEMBL28629401

SCHEMBL28629401

CC(C)(C)OC(=O)N1CCC(c2cccc(NC3CC(=O)NC3=O)c2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 7/20 0.58
CRBN Q96SW2 7/20 0.58
NAMPT P43490 1/20 0.48
MAPT P10636 2/20 0.47
KDM4E B2RXH2 1/20 0.47
THRB P10828 1/20 0.47
ALOX12 P18054 1/20 0.47
JAK2 O60674 2/20 0.46
JAK3 P52333 2/20 0.46
PTK2 Q05397 2/20 0.46
GPR119 Q8TDV5 2/20 0.44
ALDH1A1 P00352 2/20 0.43
STS P08842 1/20 0.43
NPC1 O15118 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
PTPN2 P17706 1/20 0.43
PTPN1 P18031 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22119499 1.00 DDB1 (0.58) DDB1CRBNNAMPTMAPTKDM4E
SCHEMBL23538658 0.92 DDB1 (0.69) DDB1CRBNNAMPTMAPTKDM4E
SCHEMBL28638009 0.88 DDB1 (0.64) DDB1CRBNNAMPTMAPTKDM4E
SCHEMBL22119702 0.88 DDB1 (0.64) DDB1CRBNNAMPTMAPTKDM4E
Hydrochloric Acid SCHEMBL29946980 0.87 DDB1 (0.63) DDB1CRBNNAMPT
SCHEMBL22119482 0.85 DDB1 (0.44) DDB1CRBNMAPTNPC1RAB9A
SCHEMBL25631901 0.85 DDB1 (0.60) DDB1CRBNNAMPTALOX12JAK2
SCHEMBL22144678 0.82 DDB1 (0.47) DDB1CRBNJAK2JAK3PTK2
SCHEMBL25631947 0.81 DDB1 (0.56) DDB1CRBNALOX12
SCHEMBL30257373 0.81 DDB1 (0.62) DDB1CRBNMAPTALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015338-A1 TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2026-01-15 US disclosed
US-12454521-B2 Targeted protein degradation C4 THERAPEUTICS, INC. 2025-10-28 US disclosed
US-20220372016-A1 TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2022-11-24 US disclosed
CN-113453679-A Targeted protein degradation C4医药公司 2021-09-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015338-A1 TARGETED PROTEIN DEGRADATION PSMC3, PSMA6, ADRM1 DDB1 716/4885CRBN 17/4885NAMPT 4868/4885
US-20220372016-A1 TARGETED PROTEIN DEGRADATION STUB1, MDM2, UBE3A DDB1 219/4885CRBN 55/4885NAMPT 3483/4885
US-12454521-B2 Targeted protein degradation STUB1, MDM2, UBE3A DDB1 219/4885CRBN 55/4885NAMPT 3483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.